

ESMO PRECEPTORSHIP PROGRAMME SUPPORTIVE AND PALLIATIVE CARE

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Lugano, Switzerland
16-17 April 2018

CHAIR: Karin Jordan, Germany
CO-CHAIR: Florian Strasser, Switzerland

SPEAKERS: Matti Aapro, Switzerland
Marie Fallon, United Kingdom
Berit Jordan, Germany
Stein Kaasa, Norway
Florian Scotté, France
Luzia Travado, Portugal
Annie Young, United Kingdom
Jayne Wood, United Kingdom

LEARNING OBJECTIVES

- Understand *mechanisms, risk, prevention and treatment* of the *key symptoms and syndromes* pain, fatigue, anorexia, cachexia, dyspnea, nausea, vomiting, diarrhea, skin toxicities, mucositis, neurotoxicity, venous thromboembolism, febrile neutropenia, anemia, bone complications and their *association* with cancer-disease and anticancer-treatment
- Understand integration of *screening* for and *assessment* of anticancer toxicities, symptoms and other palliative and supportive care needs, and *integration* of their management in routine oncology care
- Describe required competences of multidisciplinary and *inter-professional* teams for multimodal management
- Understand key steps to prepare patients and family members for *end-of-life* and care of the dying person
- Understand how to *communicate* with patients about illness, prognosis, coping, hope, and decisions, reflect about your own role, and how to address cultural differences
- Know the ESMO Clinical Practice *Guidelines* relevant for the topics discussed

Monday, 16 April 2018

09:00-09:55 55'	SESSION 1 - Overview of main issues of supportive and palliative care	Chairs: Karin Jordan, DE Florian Strasser, CH
5'	Introduction, goals of preceptorship and learning objectives	Karin Jordan, DE
10'	Patient centered care: understanding interplay of cancer symptoms and anticancer treatment toxicities, prevent-decide-treat-alleviate	Karin Jordan, DE Florian Strasser, CH
20'	Integration of needs-based palliative interventions in routine care: support coping, address symptoms, coordinate care, prepare EOL	Florian Strasser, CH
10'	Patient reported outcomes vs. clinical reported outcomes: what is the best to measure toxicities?	Karin Jordan, DE
10'	Participant clinical case discussion	Faculty
09:55-10:25 Coffee Break		
10:25-12:25 120'	SESSION 2 – Prevention and treatment of complications, toxicities and symptoms	Chair: Marie Fallon, UK
25'	Prophylaxis and management of febrile neutropenia: <ul style="list-style-type: none"> - Which patient should receive G-CSF? - Which antibiotics shall (not) be given? 	Matti Aapro, CH
5'	Q&A session	
25'	Anticancer therapy-induced neurotoxicity: mechanism, prevention and treatment by drugs, physical exercise	Berit Jordan, DE
5'	Q&A session	
25'	Mechanism and management of fatigue	Marie Fallon, UK
5'	Q&A session	
25'	Anaemia and thrombocytopenia caused by cancer and anticancer treatment: how to prevent and manage best?	Matti Aapro, CH
5'	Q&A session	
12:25-13:25 Lunch		
13:25-14:55 90'	SESSION 3 – Prepare for and care during end-of-life	Chair: Stein Kaasa, NO
25'	Balancing hope and coping with reality in modern oncology: integrating value-based advanced care planning in routine care	Florian Strasser, DE
5'	Q&A session	
25'	Coordination of palliative support networks for the patient and family members: role of oncologist	Jayne Wood, UK
5'	Q&A session	
25'	Planning, organization and patient management of end of life care	Stein Kaasa, NO
5'	Q&A session	
14:55-15:25 Coffee Break		

15:25-16:55 90'	SESSION 4 - Management of cancer disease and cancer-treatment related symptoms	Chair: Florian Scotté, FR
25'	Nutritional approach and medications for bone health ESMO CPGs	Matti Apro, CH
5'	Q&A session	
25'	Prevention and management of cancer chemo- and radiotherapy-induced nausea and vomiting, International Guideline update and future directions	Karin Jordan, DE
5'	Q&A session	
25'	Anticancer therapy-induced mucositis and diarrhoea: prevention and management strategies	Florian Scotté, FR
5'	Q&A session	
16:55-18:05 70'	SESSION 5 – Pain and communication	Chair: Luzia Travado, PT
30'	Management of cancer pain	Marie Fallon, UK
5'	Q&A session	
35'	Communication skills, communication in challenging situations (bad news, difficult families, desire hasten death), prevent burnout	Luzia Travado, PT
20:00	Dinner	

Tuesday, 17 April 2018

08:30-10:20 110'	SESSION 6 - Multimodal and multiprofessional management	Chair: Florian Strasser, CH
25'	Drugs to treat and relieve patients with cancer cachexia <ul style="list-style-type: none"> - Old drugs used for the cachectic cancer patients - New, cachexia mechanism-based compounds 	Marie Fallon, UK
5'	Q&A session	
25'	Nutrition in the cancer patient: how to make decisions (nutrition, anticancer drugs), when to move to invasive nutrition, value of physical training	Florian Strasser, CH
5'	Q&A session	
20'	Symptom control, essentials: delirium, dyspnoea and recurrent ascites	Jayne Wood, UK
5'	Q&A session	
20'	Collaboration of physicians and nurses in cancer care, nursing interventions and patient empowerment	Annie Young, UK
5'	Q&A session	
10:20-10:50	Coffee Break	

10:50-12:40 110'	SESSION 7 – Aspects of multi-disciplinary, patient-centered care	Chair: Annie Young, UK
20'	Prevention and management of skin toxicities, including when and how to collaborate with dermatologists	Florian Scotté, FR
5'	Q&A session	
20'	Prevention and management of thromboembolism	Annie Young, UK
5'	Q&A session	
15'	Emergencies: paravasation of anticancer agents including when to call the surgeon	Karin Jordan, DE
5'	Q&A session	
15'	Cardiovascular toxicity induced by anti-tumour therapy	Florian Scotté, FR
5'	Q&A session	
15'	Why ESMO Designated Centers of Cancer Integrated Oncology & Palliative Care	Stein Kaasa, NO
5'	Q&A session	
12:40-13:10 30'	SESSION 8 - Audience cases	Chairs: Karin Jordan, DE Florian Strasser, CH
3x10'	3 x Participant clinical case discussion	Faculty
13:10-13:20 10'	Conclusion, outlook and farewell	Chairs: Karin Jordan, DE Florian Strasser, CH
13:20-14:20	Lunch	

Note: Each 10 minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion